- Conditions
- Type 2 Diabetes
- Interventions
- Roflumilast, Alogliptin, Exenatide, Placebo to roflumilast, Placebo to alogliptin
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012
- U.S. locations
- 2
- States / cities
- Chula Vista, California • Orlando, Florida
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–22
of 22
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Diabetes
- Interventions
- Semaglutide, DPP-4 inhibitor
- Drug
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 65 Years and older
- Enrollment
- 742,670 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Diabetes Mellitus
- Interventions
- Alogliptin
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 3,323 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2011
- U.S. locations
- 62
- States / cities
- Birmingham, Alabama • Peoria, Arizona • Phoenix, Arizona + 59 more
- Conditions
- Diabetes Mellitus
- Interventions
- Alogliptin, Pioglitazone, Metformin, Placebo
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 803 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 86
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Lake Havasu City, Arizona + 83 more
- Conditions
- Type 2 Diabetes Mellitus, Cardiovascular Diseases
- Interventions
- SU, DPP4, SGLT2i, GLP-1RA, SGLT2i or GLP-1RA, Linagliptin (DPP4), Exenatide (GLP-1RA), Liraglutide (GLP-1RA), Empagliflozin (SGLT2i), Glimepiride (SU), Glipizide (SU), Glimepiride (SU) or Glipizide (SU), SU or DPP4 (excluding saxagliptin and alogliptin), Exenatide (GLP-1RA) or Liraglutide (GLP-1RA)
- Drug
- Lead sponsor
- Kaiser Permanente
- Other
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 241,981 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 6
- States / cities
- Pasadena, California • Pleasanton, California • Honolulu, Hawaii + 3 more
- Conditions
- Diabetes Mellitus
- Interventions
- Alogliptin and glyburide, Glyburide
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2007
- U.S. locations
- 54
- States / cities
- Birmingham, Alabama • Peoria, Arizona • Phoenix, Arizona + 51 more
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Alogliptin, Alogliptin placebo, Pioglitazone, Pioglitazone placebo
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 1,554 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 72
- States / cities
- Birmingham, Alabama • Columbiana, Alabama • Huntsville, Alabama + 69 more
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- DPP4, GLP-1 receptor agonist, Basal Insulin, SLGT2, SU
- Drug
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 30 Years and older
- Enrollment
- 550,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 5
- States / cities
- Wilmington, Delaware • Lexington, Kentucky • Boston, Massachusetts + 2 more
- Conditions
- Diabetes Mellitus
- Interventions
- Alogliptin and metformin, Metformin
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 527 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2007
- U.S. locations
- 40
- States / cities
- Phoenix, Arizona • Anaheim, California • Artesia, California + 37 more
- Conditions
- Diabetes Mellitus
- Interventions
- Alogliptin and pioglitazone, Pioglitazone
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 493 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2007
- U.S. locations
- 64
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Anaheim, California + 61 more
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Alogliptin Benzoate, Placebo
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 10 Years to 17 Years
- Enrollment
- 152 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2022
- U.S. locations
- 34
- States / cities
- Little Rock, Arkansas • Los Angeles, California • Palmdale, California + 31 more
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Alogliptin, Metformin, Glipizide
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 2,639 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 94
- States / cities
- Montgomery, Alabama • Muscle Shoals, Alabama • Pell City, Alabama + 91 more
- Conditions
- Diabetes Mellitus, Type 2, Cardiovascular Diseases
- Interventions
- Canagliflozin, Empagliflozin, Dapagliflozin, Dipeptidyl Peptidase-4 (DPP-4) Inhibitors, Glucagon-like Peptide-1 (GLP-1) Agonist, Anti-hyperglycemic Agents (AHA), Thiazolidinediones (TZD), Sulfonylureas (SU), Insulin
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- Not listed
- Enrollment
- 714,582 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018
- U.S. locations
- 1
- States / cities
- Titusville, New Jersey
- Conditions
- Cardiovascular Kidney Metabolic Syndrome
- Interventions
- Intervention, Active Comparator
- Drug
- Lead sponsor
- Ohio State University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 23,280,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Alogliptin
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 10 Years to 65 Years
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2013
- U.S. locations
- 7
- States / cities
- Miami, Florida • Pineallas Park, Florida • Louisville, Kentucky + 4 more
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Alogliptin, Metformin, Alogliptin Placebo, Metformin Placebo
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 784 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 109
- States / cities
- Dothan, Alabama • Muscle Shoals, Alabama • Pell City, Alabama + 106 more
- Conditions
- Diabetes Mellitus
- Interventions
- Alogliptin, Pioglitazone, Placebo
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 655 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 83
- States / cities
- Columbiana, Alabama • Hueytown, Alabama • Huntsville, Alabama + 80 more
- Conditions
- Diabetes Mellitus
- Interventions
- Alogliptin and insulin, Insulin
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 390 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2007
- U.S. locations
- 45
- States / cities
- Phoenix, Arizona • Anaheim, California • Artesia, California + 42 more
- Conditions
- Cardiovascular Events, Type2 Diabetes, Renal Disease
- Interventions
- SGLT2 inhibitor, DPP-4 inhibitor, GLP-1RA, 2nd generation SU
- Drug
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 781,430 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Diabetes Mellitus
- Interventions
- Alogliptin, Glipizide
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 65 Years to 90 Years
- Enrollment
- 441 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 36
- States / cities
- Alexander City, Alabama • Foothill Ranch, California • Huntington Park, California + 33 more
- Conditions
- Diabetes Mellitus, Type 2, Acute Coronary Syndrome
- Interventions
- Alogliptin, Placebo
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 5,380 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2013
- U.S. locations
- 292
- States / cities
- Birmingham, Alabama • Dothan, Alabama • Mobile, Alabama + 289 more
- Conditions
- Diabetes Mellitus
- Interventions
- Alogliptin, Placebo
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 329 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2007
- U.S. locations
- 50
- States / cities
- Birmingham, Alabama • Peoria, Arizona • Phoenix, Arizona + 47 more